Lexaria Bioscience (NASDAQ:LEXX) on Tuesday said an independent review board had approved the company's human clinical nicotine study.
The study, called NIC-H22-1, will compare the performance of LEXX's DehydraTECH-nicotine pouch to existing brands On! by Altria (MO) and Zyn by Swedish Match (OTCPK:SWMAY) (OTCPK:SWMAF).
The study is expected to enroll 36 cigarette smokers, who will be administered either the DehydraTECH, On! or Zyn nicotine pouch for three times over a period of weeks.
LEXX had previously announced that nicotine oral pouches using DehydraTECH technology were 10 to 20 times faster in reaching peak delivery of nicotine to bloodstream in an animal study.